Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc

Bullboard Posts

Comment by robergeaon Feb 16, 2017 12:37pm

232 Views

Post# 25855869

RE:RE:RE:RE:RE:RE:RE:RE:SP

Everybody knows that there is some speculation in the share price. We all expect that Goodman will buy something that will make the stock jump but until we know what he will be buying it is all up in the air. Current earnings and sales are not representative of the future. Question is when will he make the big acquisition. Current valuation supports cash and investments but we are not here for that and expect something accreditive.

Bullboard Posts

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload